Symic Bio
PrivateLast Round
Series B
Extension
Apr 25, 2019
Total Funding Raised
$81M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Symic Bio is a biopharmaceutical company that develops therapeutics focused on matrix biology to inhibit pathological inflammatory responses and affect matrix degradation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Symic Bio Comparables
Compare Symic Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OrthoTrophix, Inc. | 85% | |
| Biosplice Therapeutics | 82% | |
| 4Moving Biotech | 81% |
Symic Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 25, 2019 | ||||
| Series B | May 22, 2017 | ||||
| Series A Extension | Dec 1, 2015 | ||||
| Series A | Jan 5, 2015 |
Symic Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Purdue Research Foundation | Series A Extension, Series A |
| Mitsui Global Investment | Series A Extension, Series A |
| Lilly Ventures | Series A Extension, Series A |
| Ally Bridge Group | Series A Extension, Series A |
| InCube Ventures | Series A Extension, Series A |
| Cell Innovation Partners | Series B Extension |
| HEDA Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 565% MoM, reaching 1.9K.
- Jun 1, 2025
Monthly visitors grew 135% MoM.
Symic Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Symic Bio's valuation, stock price, and market status.
Is Symic Bio a public or private company?
Symic Bio is a private company.
What is the current stock price of Symic Bio?
Symic Bio is a private company, so its shares have no public market price. Caplight tracks Symic Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Symic Bio worth (valuation)?
Valuation information for Symic Bio is not publicly available.
Can I buy Symic Bio stock?
Symic Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Symic Bio's last funding round?
Symic Bio's most recent funding round was Series B Extension on April 25, 2019.
Who are the main investors in Symic Bio?
Key investors in Symic Bio include Lilly Ventures, Cell Innovation Partners.
Will Symic Bio IPO soon?
No public IPO plans have been announced for Symic Bio.
How can I track Symic Bio secondary market activity?
Caplight tracks bids, offers, and trades in Symic Bio's shares on secondary markets.